The early GO decision in CAPTIVATE de-risks the CIDP program and supports upcoming Phase 3 initiation in gMG. With multiple near-term catalysts (MMN data in 2H'26, gMG trial start, DNTH212 data), the stock may re-rate on continued clinical execution. Monitor Part B guidance for CAPTIVATE by YE'26.
Price Chart
Executive Summary
Dianthus Therapeutics reported full-year 2025 financial results and announced a positive GO decision in the Phase 3 CAPTIVATE trial of claseprubart for CIDP, based on achieving 20 confirmed responders in the interim analysis. The company has $514.4 million in cash, providing a runway into 2028, despite a widening net loss driven by increased R&D spending. Top-line data from multiple late-stage trials are expected in 2026–2028.
Key Financial Metrics
Key Facts
- Achieved early GO decision in Phase 3 CAPTIVATE trial for CIDP based on 20 confirmed responders with less than 40 participants completing Part A.
- Phase 3 trial in gMG expected to initiate mid-2026 with top-line results in 2H'28.
- Phase 2 MoMeNtum trial in MMN on track for top-line results in 2H'26.
- Phase 1 data for DNTH212 in healthy volunteers expected in 2H'26.
- Cash position of $514.4 million as of December 31, 2025, sufficient to fund operations into 2028.
- R&D expenses increased to $145.6 million in 2025 from $83.1 million in 2024, primarily due to clinical development and headcount growth.
- Net loss for 2025 was $162.3 million ($4.20 per share), up from $85.0 million ($2.55 per share) in 2024.
Financial Impact
Increased R&D spend by $62.5 million YoY; net loss nearly doubled to $162.3 million. Cash runway extended to 2028 despite higher burn.
Risk Factors
- Interim data from open-label Part A of CAPTIVATE is not randomized or controlled; final results may differ.
- No revenue from product sales; reliant on capital markets for future funding beyond 2028.
- Increased stock-based compensation contributing to higher G&A and R&D expenses.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3251709 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▼ −8.12% | ▼ −6.22% | $89.96 (−19.97%) |
Aug 11, 2026 7w ago | Insider Cluster | $112.41 $103.28 | ▲ +8.12% | ▲ +6.22% | $89.96 (+19.97%) |
Aug 10, 2026 7w ago | 144 | $108.49 $107.04 | ▼ −1.34% | ▼ −0.28% | $89.96 (−17.08%) |
Jun 29, 2026 13w ago | Press Release | $95.68 $103.87 | ▲ +8.56% | ▲ +8.84% | $89.96 (−5.98%) |
Jun 12, 2026 16w ago | 8-K | $82.07 $97.60 | ▲ +18.92% | ▲ +17.14% | $89.96 (+9.61%) |
Jun 11, 2026 16w ago | Institutional Cluster | $76.45 $100.03 | ▲ +30.84% | ▲ +28.95% | $89.96 (+17.67%) |
May 5, 2026 21w ago | 8-K | $90.42 $84.97 | ▼ −6.03% | ▼ −8.81% | $89.96 (−0.51%) |
Mar 12, 2026 29w ago | Press Release | $77.86 $90.00 | ▲ +15.59% | ▲ +12.00% | $89.96 (+15.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access